MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...
Welcome to New Music Friday, your one place to discover the biggest new song and album releases. Let's kick off with this week's singles. Is he far away? RAYE makes her long-awaited return, and she ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback